Market News & Trends
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed
Ocean Biomedical, Inc. recently announced its cancer-targeting immunotherapy antibody candidate has demonstrated effective tumor reduction against an aggressive subset of Non-Small Cell Lung Cancer (NSCLC)…
Apellis Announces US FDA Approval of the EMPAVELI Injector, a Device to Streamline Self-Administration
Apellis Pharmaceuticals, Inc. recently announced the US FDA has approved the EMPAVELI Injector, a compact, single-use, on-body device designed to enhance self-administration of….
Zevra Therapeutics Announces Interim Data From Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
Zevra Therapeutics, Inc. recently announced interim data from the open-label dose titration phase of the Phase 2 clinical trial evaluating KP1077 in patients with idiopathic…
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
Assembly Biosciences, Inc. recently announced the selection of development candidate ABI-6250 to progress to IND-enabling studies. ABI-6250, an orally bioavailable small molecule entry inhibitor, is…
Evonik Strengthens Portfolio of Nanoparticle Technologies & Services for Parenteral Drug Delivery
Evonik is strengthening its platform of parenteral drug delivery solutions with three new standard PLA-PEG di-block copolymers and a new nanoparticle formulation service using….
Bio-Rad Launches PTC Tempo 48/48 & PTC Tempo 384 Thermal Cyclers
Bio-Rad Laboratories, Inc.recently announced the launch of its PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers, designed to support PCR applications in basic and…
Investigational Treatment for Fragile X Syndrome Receives Rare Pediatric Disease Designation From FDA
Shionogi & Co., Ltd. recently announced the US FDA has granted Tetra Therapeutics Inc. Rare Pediatric Disease Designation for zatolmilast (BPN14770), an investigational treatment being…
Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 From Ongoing MYCHELANGELO I Trial
Omega Therapeutics, Inc. recently announced encouraging preliminary safety, tolerability, pharmacokinetic, and translational data from the initial two dose level cohorts (n=8) from Part 1 of its ongoing Phase 1/2 MYCHELANGELO I study evaluating….
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
Phathom Pharmaceuticals, Inc. recently announced the submission of an NDA to the FDA for vonoprazan as a daily treatment for Non-Erosive gastroesophageal reflux disease (GERD)…
bYoRNA & Dyadic Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
bYoRNA SAS and Dyadic International, Inc. recently announced they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help…
SOHM Announces Acquisition of ABBIE, a World-Class Gene-Editing Platform That Can Deliver Genetic Payloads Using Non-Viral Vectors
With this acquisition, SOHM is well-positioned as a competitive player in the $5.3 billion gene-editing market in 2023. The gene-editing market is expected to grow….
MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services
MilliporeSigma is the first CTDMO to offer integrated services for all critical stages of mRNA development, manufacturing, and commercialization, including products and….
AcuraStem Enters Into License Agreement With Takeda to Advance PIKFYVE Therapeutics
AcuraStem recently announced it has entered into a license agreement with Takeda to develop and commercialize AcuraStem’s PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide…
Coya Therapeutics Licenses Exclusive Worldwide Rights to Exosome Engineering Technology From Carnegie Mellon University
Coya Therapeutics, Inc. recently announced licensing of the exclusive, worldwide rights of a proprietary Exosome Engineering Technology from CMU with potential applications across multiple indications, including…
Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls
Clene Inc. recently announced long-term follow-up data for patients treated with CNM-Au8 30 mg for up to 133 weeks in the HEALEY ALS Platform Trial.…
Biora Therapeutics Announces Submission of IND Application for BT-600 Program Featuring NaviCap Ingestible Drug Delivery Device
Biora Therapeutics, Inc. recently announced submission of an Investigational New Drug (IND) application with the US FDA that supports the next phase of development of…
Replay Announces Partnership Between Syena & JURA Bio to Advance T Cell Receptor NK Therapies in Cancer
Replay recently announced a research collaboration between JURA Bio and Syena to develop T cell receptor (TCR) based therapies. “JURA Bio’s highly differentiated TCR discovery…
Bora Collaborates With Sunway Biotech to Launch Global Nutraceuticals Offering
Bora Health, a global design, development and distribution partner of pharmaceuticals and health foods and part of the Bora group, recently announced its merged with Sunway Biotech, a leading ingredients manufacturer and….
Revolo Biotherapeutics Announces Completion of Phase 1 Multiple Ascending Dose Clinical Trial of Immune-Resetting Drug Candidate
Revolo Biotherapeutics recently announced the completion of a Phase 1 multiple ascending dose (MAD) clinical trial evaluating the safety and tolerability of the company’s immune-resetting…
Oxford Biomedica & Institut Mérieux Enter Exclusive Negotiations With Respect to Proposed Acquisition by Oxford Biomedica of ABL Europe From Institut Mérieux as Part of Pure-Play CDMO Transformation
Oxford Biomedica plc and Institut Mérieux SA recently announced they have entered into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of…
